BioSpace - Nektar Therapeutics (CA) News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Nektar Therapeutics (CA)

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco California 94158 U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, is in Phase 2 development in chronic pain patients. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Key Statistics

Email: nektar@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics (CA)
Employees: 421
Symbol: NKTR

Industry
Biotechnology
Pharmaceutical

Segment
Human Therapeutics

Company News

Nektar Therapeutics (CA) (NKTR)' President and CEO, Howard W. Robin, to Present at the 2013 UBS Global Healthcare Conference in New York City 5/17/2013 6:43:47 AM More...

Nektar Therapeutics (CA) (NKTR) Reports Financial Results for the First Quarter of 2013 5/10/2013 6:58:03 AM More...

Nektar Therapeutics (CA) (NKTR) to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets 5/3/2013 7:26:14 AM More...

Nektar Therapeutics (CA) (NKTR) to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston 3/4/2013 6:23:02 AM More...

Nektar Therapeutics (CA) (NKTR) to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets 2/13/2013 6:49:23 AM More...

Nektar Therapeutics (CA) (NKTR) Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) 2/5/2013 10:06:07 AM More...

Nektar Therapeutics (CA) (NKTR)' President and CEO, Howard W. Robin, to Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA 1/4/2013 7:12:05 AM More...

AstraZeneca PLC (AZN), Nektar Therapeutics (CA) (NKTR) Opioid Constipation Drug May Have Failed Phase III Study 11/13/2012 8:39:31 AM More...

Nektar Therapeutics (CA) (NKTR) to Host Conference Call to Discuss The Positive Phase 3 Clinical Results for Naloxegol 11/12/2012 10:04:57 AM More...

Nektar Therapeutics (CA) (NKTR) Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer 11/7/2012 10:34:20 AM More...

1